MISSION

NBO (acronym for Nasal Bioavailability of Octreotide) Pharma Inc. was incorporated in 2021 to develop a drug for the treatment of Idiopathic Intracranial Hypertension [IIH] for which no drugs are approved. We are re-purposing an existing orphan drug – octreotide acetate – with an Intranasal [IN] formulation. IN octreotide is undergoing clinical trials for IIH.
Learn More

Announcing IIHConnect.com

IIHConnect.com is an educational resource for people living with Idiopathic Intracranial Hypertension and the physicians who treat them. The site brings together curated research, expert video, patient stories, and a searchable directory of specialists. It also features Ask Isaiah, an AI Chatbot that answers questions about IIH using a knowledge base of research and clinical resources.
Learn More

IDIOPATHIC INTRACRANIAL HYPERTENSION

Untreated IIH can lead to papilledema [bilateral optic nerve swelling]; it can be progressive and lead to enlargement of blind spots, visual obscurations, and loss of vision.
Learn More

OCTREOTIDE PROOF OF CONCEPT IN IIH PATIENTS

Six open label studies with injectable octreotide have shown the drug to be effective in lowering intracranial pressure [ICP], reducing headache, and improving visual symptoms when administered up to 3 times a day. Intranasal delivery aims to reduce the frequency of administration, enable the use of lower amounts of drug, lower systemic side effects, and avoid pain and discomfort associated with an injectable product.
Learn More

Announcing IIHConnect.com

IIHConnect.com is an educational resource for people living with Idiopathic Intracranial Hypertension and the physicians who treat them. The site brings together curated research, expert video, patient stories, and a searchable directory of specialists. It also features Ask Isaiah, an AI Chatbot that answers questions about IIH using a knowledge base of research and clinical resources.
Learn More

IDIOPATHIC INTRACRANIAL HYPERTENSION

Untreated IIH can lead to papilledema [bilateral optic nerve swelling]; it can be progressive and lead to enlargement of blind spots, visual obscurations, and loss of vision.
Learn More

OCTREOTIDE PROOF OF CONCEPT IN IIH PATIENTS

Six open label studies with injectable octreotide have shown the drug to be effective in lowering intracranial pressure [ICP], reducing headache, and improving visual symptoms when administered up to 3 times a day. Intranasal delivery aims to reduce the frequency of administration, enable the use of lower amounts of drug, lower systemic side effects, and avoid pain and discomfort associated with an injectable product.
Learn More